Drug Profile


Alternative Names: Dexmecamylamine hydrochloride; NIH-11008; S(+)-mecamylamine; S-mecamylamine; TC-5214

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targacept
  • Developer AstraZeneca; Atacama Therapeutics; Targacept
  • Class Antidepressants; Norbornanes; Small molecules
  • Mechanism of Action Alpha3beta4 nicotinic receptor antagonists; Alpha4beta2 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperhidrosis
  • Discontinued Hypertension; Major depressive disorder; Overactive bladder; Resistant hypertension

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 19 Jan 2018 Atacama Therapeutics plans a phase II trial for Hyperhidrosis in January 2018 , (NCT03404570)
  • 21 Dec 2017 Phase-II clinical trials in Hyperhidrosis in USA (PO) (NCT03404570)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top